908 Devices (MASS) Q3 2026 earnings review
908 Devices sales jump 35%, but operating losses barely shrink
908 Devices, a maker of handheld chemical analyzers for defense and safety teams, shipped a record number of tools while its operating losses barely budged. Third-quarter sales rose 35% from a year ago to $19 million as the group placed 308 core devices and about 100 newly acquired NIRLab drug scanners. Chief executive Kevin J. Knopp nudged the bottom of the full-year sales outlook higher, which by our math leaves 20% growth for the fourth quarter.
| Revenue | $19.0M +35% from a year ago |
|---|---|
| Core devices placed | 308 +75% from a year ago |
| Recurring share of revenue | 27% 35% a year ago |
| Full-year revenue outlook | Raised $0.25M middle of the range: 23% growth |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because booming hardware shipments were offset by rising sales overhead and lagging subscription growth. Keeping gross margin excluding one-offs at 58% eased worries that newer, cheaper devices would hurt factory profitability. The bad news: selling and administrative expenses climbed 31%, so the extra revenue did not shrink the $1.7 million cash operating loss, and acquisition stock payouts pushed the share count up 14%.
The question now is whether the growing base of handheld tools will finally generate higher recurring service and software revenue, or if operating costs will keep eating the hardware gains. One view is that recurring sales will rebound in the fourth quarter once a U.S. defense service pause passes its one-year mark; the other is that the business remains tied to one-off government hardware grants. Fourth-quarter recurring revenue and cash operating profit will tell.
🐂 Bull Case
Record Device Shipments Push Revenue Up 35%
908 Devices sells handheld tools that identify unknown chemicals for defense and safety workers. Chief executive Kevin J. Knopp said third-quarter results were "driven by our FTIR portfolio, with revenue growing 35% year-over-year to $19 million and device shipments reaching a new company record". FTIR, or Fourier-transform infrared spectroscopy, is a technology that uses light to test solid and liquid samples.
- Core devices placed: 308 units, up 75% from 176 a year ago
- Total installed base: 4,409 devices, up 26% from a year ago
- Product revenue: $15.8 million, up 45% from a year ago
- NIRLab devices: "Shipped approximately 100 NIRLab devices in the first full quarter following the acquisition", the company said
The jump came partly because a U.S. government shutdown depressed last year's third quarter by 4%. Even so, placing 308 core units beat every prior quarter in the company's history, and the separate NIRLab drug-testing tools accelerated from about 35 units in their first two months to 100 this quarter.
What to watch: fourth-quarter product revenue against last year's tougher comparison of $14.3 million. Holding double-digit growth without an easy comparison will show that demand for the new chemical analyzers is durable.
Gross Margins Held Firm Despite Mix Concerns
Entering the second half of the year, a standing concern was that selling more lower-priced NIRLab tools and discounted international orders would hurt profitability. Instead, gross margin held at 53%, and gross margin excluding one-offs stayed at 58%.
Compared with the second quarter, gross margin excluding one-offs rose by 1 percentage point. By our math, the cost of making products fell by 0.6 percentage points of product sales, and service costs dropped by 0.9 percentage points of service sales. Higher factory volume covered the fixed overhead of building the analyzers.
What to watch: fourth-quarter gross margin excluding one-offs against the full-year target of 56% to 57%. Another reading near 58% would show that factory scale offsets the hardware product mix.
Positives this quarter didn't test
Two standing growth drivers from earlier quarters received no broken-out numbers in the press release.
- U.S. state and local customer demand: exceeded half of total revenue last quarter, and the quarterly filing will show whether local police and fire agencies kept driving the record placements.
- International contract execution: the company booked a $6 million Asia-Pacific order for its ProtectIR analyzer after the second quarter closed, and the filing or call remarks will show how much of that order shipped in the third quarter.
🐻 Bear Case
Recurring Revenue Still Lags the Installed Base
"NIRLab is also gaining traction, both in unit volumes and pipeline, as we build a growing base of connected, recurring revenue," Knopp said. NIRLab is a Swiss maker of near-infrared drug scanners that 908 Devices bought in May to add annual software subscriptions to its hardware sales.
The quarter's numbers show that recurring revenue — ongoing sales from service contracts, accessories, and software subscriptions — is not keeping up with hardware placements. Recurring revenue rose 6% from a year ago to $5.1 million, while the installed base of core devices grew 26%. Service and contract revenue on the income statement grew 1% to $3.2 million.
Because hardware sales grew much faster, recurring revenue fell to 27% of total sales, down from 35% a year ago and 31% last quarter. By our math, recurring revenue per installed core device was $1,160 this quarter, down from $1,370 a year ago, because a pause in U.S. defense service funding for the older MX908 device continues to weigh on the base.
What to watch: fourth-quarter recurring revenue growth once the defense service pause passes its one-year mark. If recurring growth stays in the single digits after that comparison eases, the subscription shift is not lifting the total mix.
Acquisition Stock Payouts Lifted the Share Count 14%
908 Devices pays for its acquisitions partly by issuing new stock when acquired products hit sales milestones, known as contingent consideration or earnouts. In the third quarter, the weighted average share count rose 14% from a year ago and 9% from the second quarter to 41.1 million shares.
The jump reflects 3.2 million shares issued in July for the RedWave acquisition earnout, alongside stock issued to buy NIRLab. Meanwhile, the balance sheet still carries an $8.2 million long-term liability for future NIRLab milestone payouts, which the company can settle with up to $8 million in additional stock.
What to watch: total diluted shares in the fourth quarter and the fair value of the NIRLab earnout liability. Further NIRLab milestone achievements will add revenue but will dilute existing shareholders again.
Higher Sales Costs Kept Operating Losses Unchanged
Reported operating expenses fell by $8.2 million from a year ago to $15.5 million, but an accounting swing caused that drop. Non-cash charges for the changing value of acquisition milestone payouts fell by $11.0 million, shifting from a $10.7 million expense a year ago to a $0.3 million credit this quarter.
Outside of those earnout adjustments, overhead costs grew. Selling, general, and administrative expenses — sales salaries, marketing, and corporate overhead — rose $2.8 million, or 31%, to $12.0 million. Because of that spending, the operating loss excluding earnout swings was $5.8 million by our math, compared with $5.6 million a year ago, and the Adjusted EBITDA loss barely moved from $1.8 million to $1.7 million despite $4.9 million in extra revenue.
What to watch: fourth-quarter Adjusted EBITDA against last year's positive $0.7 million result. With the nine-month Adjusted EBITDA loss already at $6.1 million, the company needs a profitable fourth quarter to finish within its full-year target of a mid-single-digit million loss.
Risks this quarter didn't answer
Four standing risks from prior quarters received no new information in the third-quarter earnings release.
- Government funding dependency: over half of sales rely on state, local, and federal budgets, and the quarterly filing will show whether U.S. federal orders faced any autumn budget delays.
- Asia-Pacific order timing: the release does not state how much of the $6 million ProtectIR corrections order remains for the fourth quarter.
- AVCAD military program: the U.S. government's next steps for the Aerosol Vapor Chemical Agent Detector program were not mentioned; conference call remarks will show if a procurement path is set for 2027.
- Next-generation MX908 analyzer: previously promised for a launch late this year, the upgraded flagship device received no mention in the release.
💲 Other KPIs
Total deferred revenue — cash customers have paid upfront for multi-year service contracts and subscriptions not yet delivered — rose 24.8% from a year ago by our math, up from 20.6% growth last quarter. The balance added $1.2 million from the second quarter, showing that upfront subscription billings are building on the balance sheet ahead of revenue recognition.
Uncollected customer bills jumped 56.5% from a year ago and 52.0% since the end of 2025, outpacing the 35.3% rise in third-quarter revenue. When receivables grow much faster than sales, the company is shipping many devices near the end of the quarter or waiting longer for government agencies to pay their invoices.
The cash balance declined by $2.4 million from the second quarter and is down $13.8 million since the start of the year, though the Boston-area company still carries zero debt. The third-quarter cash outflow closely tracked the $1.7 million Adjusted EBITDA loss and the buildup in customer receivables.
🔮 Guidance
Raised. The handheld analyzer maker lifted the bottom of its full-year range by $0.5 million, putting the middle of the plan at 23.2% growth. By our math, that leaves $20.8 million for the fourth quarter, or 19.9% growth from a year ago against a tougher comparison. It is the third raise this year, and each move is smaller than the last: +$2.5M, +$0.5M, +$0.25M.
❓ Key Questions
What did NIRLab contribute to third-quarter revenue?
The company shipped about 100 NIRLab drug scanners in the quarter, up from 35 in the prior two months, but the release did not disclose the dollar revenue. Earlier plans called for NIRLab to contribute $1 million per quarter in the second half.
How much of the $6 million Asia-Pacific order shipped?
Management secured a $6 million ProtectIR order from an Asia-Pacific corrections agency after the second quarter closed. Knowing how much shipped in the third quarter tells investors how much guaranteed backlog remains to cover the $20.8 million fourth-quarter target.
Why did sales and administrative spending jump $2.8 million?
Selling, general, and administrative costs rose 31% from a year ago to $12.0 million, keeping the Adjusted EBITDA loss at $1.7 million despite record revenue. Investors need to know how much came from adding NIRLab staff versus higher sales commissions.
Is the next-generation MX908 still launching this year?
At the start of the year, management promised a commercial launch of its next-generation MX908 handheld analyzer before year-end to drive 2027 upgrades across its 3,000-unit base. The release did not mention the product.